NEW YORK & AACHEN, Germany, April 02, 2024 Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the enrollment of the first patient in the PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial (NCT05873816). The trial will enroll between 250-500 randomized patients undergoing transcatheter aortic valve replacement (TAVR) in the USA and Europe with the ProtEmbo® System, an innovative next generation cerebral embolic protection devic
Protembis GmbH (Protembis), a privately-held emerging cardiovascular medical device company, announced today the completion of a ? 30 million Series B financing round to support the enrollment of the PROTEMBO Investigational Device Exemption (IDE).
AACHEN, Germany, August 29, 2023 Protembis GmbH (Protembis) a privately-held emerging cardiovascular medical device company, announced today the appointment of Professor J Mocco MD, MS, FAANS, FAHA of Icahn School of Medicine at Mount Sinai, NY, USA as an independent member of their Board of Directors.
Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo® Cerebral Protection System yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Protembis Announces Completion of 20 Cases in European CE Mark Study With the ProtEmbo Cerebral Protection System financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.